Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01886287 · ClinicalTrials.gov registry record · Phase 2
P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01886287 is a Phase 2 study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 2 participants.
The verdict
NCT01886287, a Phase 2 study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The primary purpose of the study is to investigate the effects of high-dose octreotide on flushing, diarrhea, and quality of life in patients whose disease-related symptoms are inadequately controlled by the maximum approved dose of octreotide LAR.
Interventions
- DRUG Octreotide LAR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-12 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01886287
The ClinicalTrials.gov registry entry for NCT01886287 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Octreotide LAR is the first listed.
NCT01886287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01886287 about?
NCT01886287 is a clinical study titled "P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome". The primary purpose of the study is to investigate the effects of high-dose octreotide on flushing, diarrhea, and quality of life in patients whose disease-related symptoms are inadequately controlled by the maximum approved dose of octreotide LAR.
What is the current status of trial NCT01886287?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2013-12. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01886287?
The interventions under investigation include: Octreotide LAR (DRUG).
Who is sponsoring clinical trial NCT01886287?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.